Reference number : GC-2017-Q1-00236, amendment number : , agreement type : G, recipient legal name : Santerre, Paul (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Collaborative Health Research Projects, program name french : Projets de recherche concertée sur la santé, program purpose english : Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012,_x000D_
CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing_x000D_
the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks_x000D_
represent the main cause of CVD-related deaths, resulting in irreversible heart muscle_x000D_
damage due to the limited regenerative capacity of the heart. This can ultimately lead to endstage_x000D_
heart failure, which is currently treated using heart transplantation and ventricular assist_x000D_
devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and_x000D_
their lack of long-term suitability for all patient types are significant limitations of these_x000D_
standard treatments. Tissue engineering and the development of cardiac tissue has become_x000D_
a promising method for the repair and replacement of damaged myocardium and a means of_x000D_
preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of_x000D_
Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the_x000D_
University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital_x000D_
network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been_x000D_
shown to modulate the early immune response upon implantation, will be combined with_x000D_
cardiac cells, which will be derived from adipose stem cells, in order to develop a functional_x000D_
and vascularized cardiac patch. The properties, performance and survival of the resulting_x000D_
engineered patch will studied for their in vivo benefit., program purpose french : Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012,_x000D_
CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing_x000D_
the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks_x000D_
represent the main cause of CVD-related deaths, resulting in irreversible heart muscle_x000D_
damage due to the limited regenerative capacity of the heart. This can ultimately lead to endstage_x000D_
heart failure, which is currently treated using heart transplantation and ventricular assist_x000D_
devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and_x000D_
their lack of long-term suitability for all patient types are significant limitations of these_x000D_
standard treatments. Tissue engineering and the development of cardiac tissue has become_x000D_
a promising method for the repair and replacement of damaged myocardium and a means of_x000D_
preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of_x000D_
Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the_x000D_
University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital_x000D_
network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been_x000D_
shown to modulate the early immune response upon implantation, will be combined with_x000D_
cardiac cells, which will be derived from adipose stem cells, in order to develop a functional_x000D_
and vascularized cardiac patch. The properties, performance and survival of the resulting_x000D_
engineered patch will studied for their in vivo benefit., agreement title english : Degradable Cardiac Patch with Immuno-modulatory function, agreement title french : Degradable Cardiac Patch with Immuno-modulatory function, agreement number : CHRPJ, agreement value : 273483.0, agreement start date : 2017-04-25, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2020-2021), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada